AstraZeneca shareholders approve Alexion acquisition
AstraZeneca
10,036.00p
11:45 15/11/24
-2.49%
-256.00p
AstraZeneca’s acquisition of Alexion Pharmaceuticals is set to close in the third quarter after shareholders voted in favour of the deal.
FTSE 100
8,076.03
11:45 15/11/24
n/a
n/a
FTSE 350
4,461.73
11:45 15/11/24
n/a
n/a
FTSE All-Share
4,419.82
11:45 15/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,356.93
11:45 15/11/24
-2.21%
-438.03
Chief executive Pascal Soriot said: "The approval of the acquisition by AstraZeneca shareholders represents a significant step toward combining Alexion's leadership in complement biology and rare diseases with AstraZeneca's expertise in precision medicine and growing presence in immunology.
"We look forward to together advancing life-changing science and bringing even more medicines to patients globally."
The pharmaceuticals giant announced in December 2020 that it had agreed to buy Alexion in a $39bn deal to expand its scientific presence in immunology.